Levothyroxine dosage and the limitations of current bioequivalence standards

Nature Clinical Practice Endocrinology and Metabolism

Volumn 2, Issue 9, 2006, Pages 474-475

  Hennessey, James V ^a,b  

^a RHODE ISLAND HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; LEVOTHYROXINE SODIUM; LIOTHYRONINE; THYROXINE; UNITHROID;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CLINICAL PRACTICE; DOSIMETRY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG FORMULATION; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOTHYROIDISM; PATIENT SAFETY; PRESCRIPTION; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT OUTCOME;

BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY; HUMANS; THERAPEUTIC EQUIVALENCY; THYROTROPIN; THYROXINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33748452038     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0273     Document Type: Short Survey

References (10)

1. Hennessey JV (2003) Levothyroxine a new drug? Since when? How could that be? Thyroid 13: 279-282
2. US Department of Health and Human Services, FDA, and Center for Drug Evaluation and Research (2002) Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations [http://www.fda.gov/cder/guidance/4964dft.pdf] (accessed 19 July 2006)
3. FDA (2005) Itinery for the joint public meeting on equivalence of levothyroxine sodium products [http://www.fda.gov/ohrms/dockets/dockets/05n0137/ 05n-0137-lst0001.pdf] (accessed 19 July 2006)
4. FDA (2005) Code of federal regulations, title 21, vol 5, subchapter D, part 320 [www.accessdata. fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch. cfm?CFRPart=320&show] (accessed 19 July 2006)
5. Carr D et al. (1988) Fine adjustment of thyroxine replacement dosage: comparison of the thyrotropin releasing hormone test using a sensitive thyrotropin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol 28: 325-333
6. Henderson JD and Esham RH (2001) Generic drug substitution: issues for problematic drugs. South Med J 94: 16-21
7. FDA (2003) Advisory committee for pharmaceutical science 12-13 March 2003 [http://www.fda.gov/ohrms/dockets/ac/03/briefing/3926B1_01_H-FDA-Additional% 20Information.doc] (accessed 19 July 2006)
8. Blakesley VA et al. (2004) Are bioequivalalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable? Thyroid 14: 191-200
9. FDA (2006) Drugs@FDA [www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm] (accessed 19 July 2006)
10. American Association of Clinical Endocrinologists, the Endocrine Society and the American Thyroid Association (2005) Joint position statement on the use and interchangeability of thyroxine products [http://www.thyroid.org/ professionals/advocacy/04_12_08_thyroxine.html] (accessed 19 July 2006)